Teva/Xenon’s Pain Ointment Failure Leaves Sparser Nav1.7 Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Once highly anticipated as an alternative mechanism for pain, the Nav1.7 target suffered another blow with Teva/Xenon’s failure of TV-45070 in osteoarthritis, though the class may still work in neuropathic pain.